Coave Therapeutics

Coave Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for rare ocular and CNS (central nervous system) diseases. We are pushing the boundaries of gene therapy by applying our AAV-ligand conjugate platform (ALIGATER), which enables targeted delivery, enhanced gene transduction, and tissue distribution to improve the efficacy of advanced gene therapies for rare diseases. Our strategy is to advance a range of novel therapies targeting rare ocular and CNS diseases, where targeted gene therapy has the potential to be most effective, addresses significant unmet needs, and will successfully and rapidly validate our ALIGATER platform.